Harmony Biosciences Holdings, Inc. (HRMY) Stock Score, Valuation & Financial Research
Harmony Biosciences Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 67/100.
Quick answer for HRMY
Harmony Biosciences Holdings, Inc. currently has a Wall Street Score of 67/100. The stored market price is $41.52. Its financial score is 42/100. Its valuation score is 93/100. The latest WSS change is +0.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What Harmony Biosciences Holdings, Inc. does
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
HRMY financial snapshot
- Wall Street Score:
- 67/100
- Current price:
- $41.52
- Market capitalization:
- $2.40B
- Revenue:
- $959.9M
- Net income:
- $181.3M
- Free cash flow:
- $347.9M
- Cash:
- $549.8M
- Total debt:
- $154.0M
- EPS:
- 2.76
- P/E ratio:
- 15.0x
- Financial score:
- 42/100
- Valuation score:
- 93/100
- Revenue score:
- 48/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $347.9M, showing positive cash generation.
- The balance sheet shows $549.8M of cash versus $154.0M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.4 points: HRMY increased 0.4 points because Revenue improved by 9.1 points, Capital improved by 8 points, Buffett improved by 2 points.
What the numbers mean
Its current valuation score is 93/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 42/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research HRMY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.